4basebio PLC (LON:4BB - Get Free Report) traded up 2.3% during trading on Wednesday . The stock traded as high as GBX 1,007.50 ($13.52) and last traded at GBX 1,007.50 ($13.52). 14 shares traded hands during trading, a decline of 99% from the average session volume of 970 shares. The stock had previously closed at GBX 985 ($13.22).
Analysts Set New Price Targets
Separately, Royal Bank Of Canada reiterated an "outperform" rating and set a GBX 1,600 ($21.47) price objective on shares of 4basebio in a research note on Thursday, March 13th.
View Our Latest Stock Analysis on 4basebio
4basebio Price Performance
The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The firm has a market capitalization of £129.06 million, a price-to-earnings ratio of -1,291.67 and a beta of 1.09. The company's 50 day moving average is GBX 1,105.81 and its 200-day moving average is GBX 1,151.14.
4basebio (LON:4BB - Get Free Report) last released its quarterly earnings data on Tuesday, May 27th. The company reported GBX (0.94) (($0.01)) earnings per share (EPS) for the quarter. Equities research analysts anticipate that 4basebio PLC will post -3.43 earnings per share for the current year.
Insider Transactions at 4basebio
In other news, insider Heikki Lanckriet purchased 2,400 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The stock was acquired at an average cost of GBX 1,205 ($16.17) per share, with a total value of £28,920 ($38,808.37). 68.44% of the stock is currently owned by corporate insiders.
About 4basebio
(
Get Free Report)
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 4basebio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4basebio wasn't on the list.
While 4basebio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
